From Sanfilippo News: Allievex, a new clinical-stage biotechnology company founded by Pappas Capital, will continue the clinical program of BioMarin Pharmaceutical‘s tralesinidase alfa (formerly known as BMN 250) for the treatment of people with Sanfilippo syndrome type B. Allievex has obtained an exclusive worldwide license for tralesinidase alfa from BioMarin, and will assume all financial obligations associated with the therapy’s development and commercialization, and manage all studies in the clinical program, which will continue uninterrupted. Read the full article here.
